TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN

<p class="MsoNormal" style="text-align: justify; line-height: 200%; margin: 0cm 0cm 0pt;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span lang="EN-GB" style="mso-...

Full description

Saved in:
Bibliographic Details
Main Authors: Hela Ben Abid, Zaher Belhadjali, Samia Menif, Naouel Ben Salah, Raihane Ben Lakhal, Lamia Aissaoui, Hend Ben Neji, Zarrouk Mohamed, Kacem Karima, Yosr Ben Abdennebi, Ramzi Ben Amor, Hèla Ghédira, Ramzi Jeddi, Emna Gouider, Raouf Hafsia, Ali Saad, Pierre Fenaux, Balkis Meddeb
Format: Article
Language:English
Published: PAGEPress Publications 2011-01-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:http://www.mjhid.org/article/view/8662
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850215583587500032
author Hela Ben Abid
Zaher Belhadjali
Samia Menif
Naouel Ben Salah
Raihane Ben Lakhal
Lamia Aissaoui
Hend Ben Neji
Zarrouk Mohamed
Kacem Karima
Yosr Ben Abdennebi
Ramzi Ben Amor
Hèla Ghédira
Ramzi Jeddi
Emna Gouider
Raouf Hafsia
Ali Saad
Pierre Fenaux
Balkis Meddeb
author_facet Hela Ben Abid
Zaher Belhadjali
Samia Menif
Naouel Ben Salah
Raihane Ben Lakhal
Lamia Aissaoui
Hend Ben Neji
Zarrouk Mohamed
Kacem Karima
Yosr Ben Abdennebi
Ramzi Ben Amor
Hèla Ghédira
Ramzi Jeddi
Emna Gouider
Raouf Hafsia
Ali Saad
Pierre Fenaux
Balkis Meddeb
author_sort Hela Ben Abid
collection DOAJ
description <p class="MsoNormal" style="text-align: justify; line-height: 200%; margin: 0cm 0cm 0pt;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span lang="EN-GB" style="mso-ansi-language: EN-GB;">In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). From 2004, 51 patients with confirmed APL either by t(15;17) or PML/RARA were treated according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining seven patients had early death (one died before treatment onset): four caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage.</span><span lang="EN-GB" style="font-family: AdvP497E2; mso-bidi-font-family: AdvP497E2; mso-ansi-language: EN-GB;"> Multivariate analysis revealed that female gender (P=0.045), baseline WBC> 10 G/L ( </span><span lang="EN-GB" style="font-family: AdvP497E3; mso-bidi-font-family: AdvP497E3; mso-ansi-language: EN-GB;">P=0.041</span><span lang="EN-GB" style="font-family: AdvP497E2; mso-bidi-font-family: AdvP497E2; mso-ansi-language: EN-GB;">) and serum creatinine > 1.4mg/dl ( P=0.021) were predictive of mortality during induction. </span><span lang="EN-GB" style="mso-ansi-language: EN-GB;"><span style="mso-spacerun: yes;"> </span>DS was observed in 16 patients (32%) after a median onset time of 15 days from treatment onset (range, 2–29). Body mass index ≥ 30 (P=0.01) was the only independent predictor of DS. Occurrence of hypertensive peaks significantly predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). With a median follow-up of<span style="mso-spacerun: yes;"> </span>50 months, 5 year cumulative incidence of relapse, event free and overall survival were 4.7%, 74% and 78%, respectively.</span></span></span></p>
format Article
id doaj-art-710d67a3c5c64dc985e0c4da4e3347e3
institution OA Journals
issn 2035-3006
language English
publishDate 2011-01-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-710d67a3c5c64dc985e0c4da4e3347e32025-08-20T02:08:35ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-01-0131e2011033e2011033TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMENHela Ben AbidZaher BelhadjaliSamia MenifNaouel Ben SalahRaihane Ben LakhalLamia AissaouiHend Ben NejiZarrouk MohamedKacem KarimaYosr Ben AbdennebiRamzi Ben AmorHèla GhédiraRamzi JeddiEmna GouiderRaouf HafsiaAli SaadPierre FenauxBalkis Meddeb<p class="MsoNormal" style="text-align: justify; line-height: 200%; margin: 0cm 0cm 0pt;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span lang="EN-GB" style="mso-ansi-language: EN-GB;">In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). From 2004, 51 patients with confirmed APL either by t(15;17) or PML/RARA were treated according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining seven patients had early death (one died before treatment onset): four caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage.</span><span lang="EN-GB" style="font-family: AdvP497E2; mso-bidi-font-family: AdvP497E2; mso-ansi-language: EN-GB;"> Multivariate analysis revealed that female gender (P=0.045), baseline WBC> 10 G/L ( </span><span lang="EN-GB" style="font-family: AdvP497E3; mso-bidi-font-family: AdvP497E3; mso-ansi-language: EN-GB;">P=0.041</span><span lang="EN-GB" style="font-family: AdvP497E2; mso-bidi-font-family: AdvP497E2; mso-ansi-language: EN-GB;">) and serum creatinine > 1.4mg/dl ( P=0.021) were predictive of mortality during induction. </span><span lang="EN-GB" style="mso-ansi-language: EN-GB;"><span style="mso-spacerun: yes;"> </span>DS was observed in 16 patients (32%) after a median onset time of 15 days from treatment onset (range, 2–29). Body mass index ≥ 30 (P=0.01) was the only independent predictor of DS. Occurrence of hypertensive peaks significantly predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). With a median follow-up of<span style="mso-spacerun: yes;"> </span>50 months, 5 year cumulative incidence of relapse, event free and overall survival were 4.7%, 74% and 78%, respectively.</span></span></span></p>http://www.mjhid.org/article/view/8662Leukemia
spellingShingle Hela Ben Abid
Zaher Belhadjali
Samia Menif
Naouel Ben Salah
Raihane Ben Lakhal
Lamia Aissaoui
Hend Ben Neji
Zarrouk Mohamed
Kacem Karima
Yosr Ben Abdennebi
Ramzi Ben Amor
Hèla Ghédira
Ramzi Jeddi
Emna Gouider
Raouf Hafsia
Ali Saad
Pierre Fenaux
Balkis Meddeb
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
Mediterranean Journal of Hematology and Infectious Diseases
Leukemia
title TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
title_full TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
title_fullStr TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
title_full_unstemmed TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
title_short TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
title_sort treatment of acute promyelocytic leukemia with aida based regimen
topic Leukemia
url http://www.mjhid.org/article/view/8662
work_keys_str_mv AT helabenabid treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT zaherbelhadjali treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT samiamenif treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT naouelbensalah treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT raihanebenlakhal treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT lamiaaissaoui treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT hendbenneji treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT zarroukmohamed treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT kacemkarima treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT yosrbenabdennebi treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT ramzibenamor treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT helaghedira treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT ramzijeddi treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT emnagouider treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT raoufhafsia treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT alisaad treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT pierrefenaux treatmentofacutepromyelocyticleukemiawithaidabasedregimen
AT balkismeddeb treatmentofacutepromyelocyticleukemiawithaidabasedregimen